{name}
{subtitle}
Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer
city
~25 mi. (Tlalpan, Mexico, +247 more cities)
facility
Local Institution
biomarker
ER Positive, +1 more biomarker
drug
anthracycline, +4 more drugs
drug type
chemotherapy, +2 more types
Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer
city
~25 mi. (Tlalpan, Mexico, +172 more cities)
facility
Local Institution
drug
cisplatin, +3 more drugs
drug type
chemotherapy, +1 more type
A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread
city
~25 mi. (Tlalpan, Mexico, +84 more cities)
facility
Local Institution
drug
nivolumab, +1 more drug
drug type
immunotherapy, +1 more type
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
city
~34 mi. (Mexico City, Mexico, +192 more cities)
facility
Grupo Medico Camino Sc
biomarker
ER Positive, +1 more biomarker
drug
abemaciclib, +1 more drug
drug type
hormone therapy, +1 more type
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
city
~34 mi. (Mexico City, Mexico, +235 more cities)
facility
Instituto Nacional De Cancerologia de Mexico
drug
abiraterone, +9 more drugs
drug type
hormone therapy, +2 more types
Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-small Cell Lung Cancer
city
~34 mi. (Mexico City, Mexico, +151 more cities)
facility
GSK Investigational Site
drug
niraparib, +1 more drug
drug type
immunotherapy, +1 more type
A Study to Compare Bempegaldesleukin (BEMPEG: NKTR-214) Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Kidney Cancer That is Advanced or Has Spread
city
~34 mi. (Mexico City, Mexico, +49 more cities)
facility
Local Institution
drug
axitinib, +3 more drugs
drug type
immunotherapy, +2 more types